Literature DB >> 6197309

Reversibility of the interaction of CGP 11305 A with MAO A in vivo.

P C Waldmeier, J J Feldtrauer, K Stoecklin, E Paul.   

Abstract

The aim of this study was to resolve the apparent discrepancy between the short duration of action of the MAO inhibitory effect of CGP 11305 A in vivo and its irreversible interaction with the enzyme in vitro. When rats were treated with CGP 11305 A 2 h prior to clorgyline administration and MAO activity was determined 46 h thereafter, MAO A in brains and livers was protected from inhibition by clorgyline provided the dose relation was adequate. However, if clorgyline doses were equal to or higher than those of CGP 11305 A, there was only partial or no protection despite the fact that the doses of CGP 11305 A blocked MAO A nearly completely at the moment of clorgyline administration. Using a different approach, it was found that dopamine and serotonin released from their stores in rat striatum by tetrabenazine could displace CGP 11305 A from the MAO A active site in vivo, in contrast to clorgyline. These results suggest that the interaction of CGP 11305 A with MAO in vivo is reversible and competitive.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6197309     DOI: 10.1016/0014-2999(83)90446-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Enhancement of 5-HT-induced anorexia: a test of the reversibility of monoamine oxidase inhibitors.

Authors:  P J Fletcher; P H Yu
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 2.  Brofaromine--a review of its pharmacological properties and therapeutic use.

Authors:  H P Volz; C H Gleiter; P C Waldmeier; M Struck; H J Möller
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain.

Authors:  N Bel; F Artigas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

4.  Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain.

Authors:  P C Waldmeier; P A Baumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

5.  On the reversibility of reversible MAO inhibitors.

Authors:  P C Waldmeier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.